Format
Sort by
Items per page

Send to

Choose Destination

Best matches for Yki‐Järvinen H[au]:

Nutritional Modulation of Non-Alcoholic Fatty Liver Disease and Insulin Resistance. Yki-Järvinen H et al. Nutrients. (2015)

Non-alcoholic fatty liver disease as a cause and a consequence of metabolic syndrome. Yki-Järvinen H et al. Lancet Diabetes Endocrinol. (2014)

Non-alcoholic fatty liver disease and risk of type 2 diabetes. Lallukka S et al. Best Pract Res Clin Endocrinol Metab. (2016)

Search results

Items: 1 to 50 of 399

1.

Metabolomes of mitochondrial diseases and inclusion body myositis patients: treatment targets and biomarkers.

Buzkova J, Nikkanen J, Ahola S, Hakonen AH, Sevastianova K, Hovinen T, Yki-Järvinen H, Pietiläinen KH, Lönnqvist T, Velagapudi V, Carroll CJ, Suomalainen A.

EMBO Mol Med. 2018 Dec;10(12). pii: e9091. doi: 10.15252/emmm.201809091.

2.

Diabetes, Liver Cancer, and Cirrhosis: What Next?

Yki-Järvinen H, Luukkonen PK.

Hepatology. 2018 Oct;68(4):1220-1222. doi: 10.1002/hep.30136. No abstract available.

PMID:
30070729
3.

Saturated Fat Is More Metabolically Harmful for the Human Liver Than Unsaturated Fat or Simple Sugars.

Luukkonen PK, Sädevirta S, Zhou Y, Kayser B, Ali A, Ahonen L, Lallukka S, Pelloux V, Gaggini M, Jian C, Hakkarainen A, Lundbom N, Gylling H, Salonen A, Orešič M, Hyötyläinen T, Orho-Melander M, Rissanen A, Gastaldelli A, Clément K, Hodson L, Yki-Järvinen H.

Diabetes Care. 2018 Aug;41(8):1732-1739. doi: 10.2337/dc18-0071. Epub 2018 May 29.

PMID:
29844096
4.

Predictors of Liver Fat and Stiffness in Non-Alcoholic Fatty Liver Disease (NAFLD) - an 11-Year Prospective Study.

Lallukka S, Sädevirta S, Kallio MT, Luukkonen PK, Zhou Y, Hakkarainen A, Lundbom N, Orho-Melander M, Yki-Järvinen H.

Sci Rep. 2017 Nov 6;7(1):14561. doi: 10.1038/s41598-017-14706-0.

5.

Fat accumulates preferentially in the right rather than the left liver lobe in non-diabetic subjects.

Hua B, Hakkarainen A, Zhou Y, Lundbom N, Yki-Järvinen H.

Dig Liver Dis. 2018 Feb;50(2):168-174. doi: 10.1016/j.dld.2017.08.030. Epub 2017 Aug 23.

PMID:
28964678
6.

Serum Insulin Bioassay Reflects Insulin Sensitivity and Requirements in Type 1 Diabetes.

Janssen JAMJL, Llauradó G, Varewijck AJ, Groop PH, Forsblom C, Fernández-Veledo S, van den Dungen ESR, Vendrell J, Hofland LJ, Yki-Järvinen H.

J Clin Endocrinol Metab. 2017 Oct 1;102(10):3814-3821. doi: 10.1210/jc.2017-00892.

PMID:
28938465
7.

Better glycaemic control and less hypoglycaemia with insulin glargine 300 U/mL vs glargine 100 U/mL: 1-year patient-level meta-analysis of the EDITION clinical studies in people with type 2 diabetes.

Ritzel R, Roussel R, Giaccari A, Vora J, Brulle-Wohlhueter C, Yki-Järvinen H.

Diabetes Obes Metab. 2018 Mar;20(3):541-548. doi: 10.1111/dom.13105. Epub 2017 Oct 5. Review.

8.

Use of HOMA-IR to diagnose non-alcoholic fatty liver disease: a population-based and inter-laboratory study.

Isokuortti E, Zhou Y, Peltonen M, Bugianesi E, Clement K, Bonnefont-Rousselot D, Lacorte JM, Gastaldelli A, Schuppan D, Schattenberg JM, Hakkarainen A, Lundbom N, Jousilahti P, Männistö S, Keinänen-Kiukaanniemi S, Saltevo J, Anstee QM, Yki-Järvinen H.

Diabetologia. 2017 Oct;60(10):1873-1882. doi: 10.1007/s00125-017-4340-1. Epub 2017 Jun 29.

PMID:
28660493
9.

Gene expression profile of subcutaneous adipose tissue in BMI-discordant monozygotic twin pairs unravels molecular and clinical changes associated with sub-types of obesity.

Muniandy M, Heinonen S, Yki-Järvinen H, Hakkarainen A, Lundbom J, Lundbom N, Kaprio J, Rissanen A, Ollikainen M, Pietiläinen KH.

Int J Obes (Lond). 2017 Aug;41(8):1176-1184. doi: 10.1038/ijo.2017.95. Epub 2017 Apr 25.

PMID:
28439093
10.

Impaired hepatic lipid synthesis from polyunsaturated fatty acids in TM6SF2 E167K variant carriers with NAFLD.

Luukkonen PK, Zhou Y, Nidhina Haridas PA, Dwivedi OP, Hyötyläinen T, Ali A, Juuti A, Leivonen M, Tukiainen T, Ahonen L, Scott E, Palmer JM, Arola J, Orho-Melander M, Vikman P, Anstee QM, Olkkonen VM, Orešič M, Groop L, Yki-Järvinen H.

J Hepatol. 2017 Jul;67(1):128-136. doi: 10.1016/j.jhep.2017.02.014. Epub 2017 Feb 22.

PMID:
28235613
11.

Out of the frying pan: dietary saturated fat influences nonalcoholic fatty liver disease.

Parks E, Yki-Järvinen H, Hawkins M.

J Clin Invest. 2017 Feb 1;127(2):454-456. doi: 10.1172/JCI92407. Epub 2017 Jan 23.

12.

Obesity/insulin resistance rather than liver fat increases coagulation factor activities and expression in humans.

Lallukka S, Luukkonen PK, Zhou Y, Isokuortti E, Leivonen M, Juuti A, Hakkarainen A, Orho-Melander M, Lundbom N, Olkkonen VM, Lassila R, Yki-Järvinen H.

Thromb Haemost. 2017 Jan 26;117(2):286-294. doi: 10.1160/TH16-09-0716. Epub 2016 Dec 8.

PMID:
27929200
13.

Influence of Ethnicity on the Accuracy of Non-Invasive Scores Predicting Non-Alcoholic Fatty Liver Disease.

Xia MF, Yki-Järvinen H, Bian H, Lin HD, Yan HM, Chang XX, Zhou Y, Gao X.

PLoS One. 2016 Aug 31;11(8):e0160526. doi: 10.1371/journal.pone.0160526. eCollection 2016.

14.

The MBOAT7 variant rs641738 alters hepatic phosphatidylinositols and increases severity of non-alcoholic fatty liver disease in humans.

Luukkonen PK, Zhou Y, Hyötyläinen T, Leivonen M, Arola J, Orho-Melander M, Orešič M, Yki-Järvinen H.

J Hepatol. 2016 Dec;65(6):1263-1265. doi: 10.1016/j.jhep.2016.07.045. Epub 2016 Aug 9. No abstract available.

PMID:
27520876
15.

Non-alcoholic fatty liver disease and risk of type 2 diabetes.

Lallukka S, Yki-Järvinen H.

Best Pract Res Clin Endocrinol Metab. 2016 Jun;30(3):385-95. doi: 10.1016/j.beem.2016.06.006. Epub 2016 Jun 23. Review.

PMID:
27432073
16.

Noninvasive Detection of Nonalcoholic Steatohepatitis Using Clinical Markers and Circulating Levels of Lipids and Metabolites.

Zhou Y, Orešič M, Leivonen M, Gopalacharyulu P, Hyysalo J, Arola J, Verrijken A, Francque S, Van Gaal L, Hyötyläinen T, Yki-Järvinen H.

Clin Gastroenterol Hepatol. 2016 Oct;14(10):1463-1472.e6. doi: 10.1016/j.cgh.2016.05.046. Epub 2016 Jun 16.

PMID:
27317851
17.

Definitions of Normal Liver Fat and the Association of Insulin Sensitivity with Acquired and Genetic NAFLD-A Systematic Review.

Petäjä EM, Yki-Järvinen H.

Int J Mol Sci. 2016 Apr 27;17(5). pii: E633. doi: 10.3390/ijms17050633. Review.

18.

Diagnosis of non-alcoholic fatty liver disease (NAFLD).

Yki-Järvinen H.

Diabetologia. 2016 Jun;59(6):1104-11. doi: 10.1007/s00125-016-3944-1. Epub 2016 Apr 18. Review.

PMID:
27091184
19.

Phosphorylated IGFBP-1 as a non-invasive predictor of liver fat in NAFLD.

Petäjä EM, Zhou Y, Havana M, Hakkarainen A, Lundbom N, Ihalainen J, Yki-Järvinen H.

Sci Rep. 2016 Apr 19;6:24740. doi: 10.1038/srep24740.

20.

Efficacy and Safety of Flexible Versus Fixed Dosing Intervals of Insulin Glargine 300 U/mL in People with Type 2 Diabetes.

Riddle MC, Bolli GB, Home PD, Bergenstal RM, Ziemen M, Muehlen-Bartmer I, Wardecki M, Vinet L, Jeandidier N, Yki-Järvinen H.

Diabetes Technol Ther. 2016 Apr;18(4):252-7. doi: 10.1089/dia.2015.0290. Epub 2016 Feb 3.

21.

Genome-scale study reveals reduced metabolic adaptability in patients with non-alcoholic fatty liver disease.

Hyötyläinen T, Jerby L, Petäjä EM, Mattila I, Jäntti S, Auvinen P, Gastaldelli A, Yki-Järvinen H, Ruppin E, Orešič M.

Nat Commun. 2016 Feb 3;7:8994. doi: 10.1038/ncomms9994.

22.

Continuous Grading of Early Fibrosis in NAFLD Using Label-Free Imaging: A Proof-of-Concept Study.

Pirhonen J, Arola J, Sädevirta S, Luukkonen P, Karppinen SM, Pihlajaniemi T, Isomäki A, Hukkanen M, Yki-Järvinen H, Ikonen E.

PLoS One. 2016 Jan 25;11(1):e0147804. doi: 10.1371/journal.pone.0147804. eCollection 2016.

23.

Hepatic ceramides dissociate steatosis and insulin resistance in patients with non-alcoholic fatty liver disease.

Luukkonen PK, Zhou Y, Sädevirta S, Leivonen M, Arola J, Orešič M, Hyötyläinen T, Yki-Järvinen H.

J Hepatol. 2016 May;64(5):1167-1175. doi: 10.1016/j.jhep.2016.01.002. Epub 2016 Jan 11.

PMID:
26780287
24.

MicroRNA-192* impairs adipocyte triglyceride storage.

Mysore R, Zhou Y, Sädevirta S, Savolainen-Peltonen H, Nidhina Haridas PA, Soronen J, Leivonen M, Sarin AP, Fischer-Posovszky P, Wabitsch M, Yki-Järvinen H, Olkkonen VM.

Biochim Biophys Acta. 2016 Apr;1861(4):342-51. doi: 10.1016/j.bbalip.2015.12.019. Epub 2015 Dec 30.

PMID:
26747651
25.

Novel hepatic microRNAs upregulated in human nonalcoholic fatty liver disease.

Soronen J, Yki-Järvinen H, Zhou Y, Sädevirta S, Sarin AP, Leivonen M, Sevastianova K, Perttilä J, Laurila PP, Sigruener A, Schmitz G, Olkkonen VM.

Physiol Rep. 2016 Jan;4(1). pii: e12661. doi: 10.14814/phy2.12661.

26.

Effect of 3 Years of Treatment With Exenatide on Postprandial Glucagon Levels.

Smits MM, Bunck MC, Diamant M, Corner A, Eliasson B, Heine RJ, Smith U, Yki-Järvinen H, van Raalte DH.

Diabetes Care. 2016 Mar;39(3):e42-3. doi: 10.2337/dc15-2489. Epub 2015 Dec 30. No abstract available.

PMID:
26721816
27.

Diagnosis of nonalcoholic fatty liver disease (NAFLD).

Yki-Järvinen H.

Duodecim. 2016;132(22):2099-106. Review.

PMID:
29190058
28.

Efficacy and safety of linagliptin as add-on therapy to basal insulin and metformin in people with Type 2 diabetes.

Durán-Garcia S, Lee J, Yki-Järvinen H, Rosenstock J, Hehnke U, Thiemann S, Patel S, Woerle HJ.

Diabet Med. 2016 Jul;33(7):926-33. doi: 10.1111/dme.13041. Epub 2016 Jan 7.

PMID:
26605991
29.

Nutritional Modulation of Non-Alcoholic Fatty Liver Disease and Insulin Resistance.

Yki-Järvinen H.

Nutrients. 2015 Nov 5;7(11):9127-38. doi: 10.3390/nu7115454. Review.

30.

Heterogeneity of non-alcoholic fatty liver disease.

Yki-Järvinen H, Luukkonen PK.

Liver Int. 2015 Dec;35(12):2498-500. doi: 10.1111/liv.12970. No abstract available.

PMID:
26386359
31.

Regulation of Angiopoietin-Like Proteins (ANGPTLs) 3 and 8 by Insulin.

Nidhina Haridas PA, Soronen J, Sädevirta S, Mysore R, Quagliarini F, Pasternack A, Metso J, Perttilä J, Leivonen M, Smas CM, Fischer-Posovszky P, Wabitsch M, Ehnholm C, Ritvos O, Jauhiainen M, Olkkonen VM, Yki-Järvinen H.

J Clin Endocrinol Metab. 2015 Oct;100(10):E1299-307. doi: 10.1210/jc.2015-1254. Epub 2015 Jul 23.

PMID:
26204133
32.

Glycaemic control and hypoglycaemia with new insulin glargine 300 U/ml versus insulin glargine 100 U/ml in people with type 2 diabetes using basal insulin and oral antihyperglycaemic drugs: the EDITION 2 randomized 12-month trial including 6-month extension.

Yki-Järvinen H, Bergenstal RM, Bolli GB, Ziemen M, Wardecki M, Muehlen-Bartmer I, Maroccia M, Riddle MC.

Diabetes Obes Metab. 2015 Dec;17(12):1142-9. doi: 10.1111/dom.12532. Epub 2015 Sep 14.

33.

Low Levels of Unmodified Insulin Glargine in Plasma of People With Type 2 Diabetes Requiring High Doses of Basal Insulin.

Lucidi P, Porcellati F, Yki-Järvinen H, Riddle MC, Candeloro P, Marinelli Andreoli A, Bolli GB, Fanelli CG.

Diabetes Care. 2015 Jul;38(7):e96-7. doi: 10.2337/dc14-2662. No abstract available.

PMID:
26106233
34.

The influence of sample collection methodology and sample preprocessing on the blood metabolic profile.

Jørgenrud B, Jäntti S, Mattila I, Pöhö P, Rønningen KS, Yki-Järvinen H, Orešič M, Hyötyläinen T.

Bioanalysis. 2015;7(8):991-1006. doi: 10.4155/bio.15.16.

PMID:
25966010
35.

Combination of the dipeptidyl peptidase-4 inhibitor linagliptin with insulin-based regimens in type 2 diabetes and chronic kidney disease.

McGill JB, Yki-Järvinen H, Crowe S, Woerle HJ, von Eynatten M.

Diab Vasc Dis Res. 2015 Jul;12(4):249-57. doi: 10.1177/1479164115579001. Epub 2015 May 4.

PMID:
25941160
36.

Patient-level meta-analysis of the EDITION 1, 2 and 3 studies: glycaemic control and hypoglycaemia with new insulin glargine 300 U/ml versus glargine 100 U/ml in people with type 2 diabetes.

Ritzel R, Roussel R, Bolli GB, Vinet L, Brulle-Wohlhueter C, Glezer S, Yki-Järvinen H.

Diabetes Obes Metab. 2015 Sep;17(9):859-67. doi: 10.1111/dom.12485. Epub 2015 Jun 16.

37.
38.

Ketone body production is differentially altered in steatosis and non-alcoholic steatohepatitis in obese humans.

Männistö VT, Simonen M, Hyysalo J, Soininen P, Kangas AJ, Kaminska D, Matte AK, Venesmaa S, Käkelä P, Kärjä V, Arola J, Gylling H, Cederberg H, Kuusisto J, Laakso M, Yki-Järvinen H, Ala-Korpela M, Pihlajamäki J.

Liver Int. 2015 Jul;35(7):1853-61. doi: 10.1111/liv.12769. Epub 2015 Jan 20.

PMID:
25533197
39.

Circulating triacylglycerol signatures and insulin sensitivity in NAFLD associated with the E167K variant in TM6SF2.

Zhou Y, Llauradó G, Orešič M, Hyötyläinen T, Orho-Melander M, Yki-Järvinen H.

J Hepatol. 2015 Mar;62(3):657-63. doi: 10.1016/j.jhep.2014.10.010. Epub 2014 Oct 19.

PMID:
25457209
40.

Liver fat content and hepatic insulin sensitivity in overweight patients with type 1 diabetes.

Llauradó G, Sevastianova K, Sädevirta S, Hakkarainen A, Lundbom N, Orho-Melander M, Groop PH, Forsblom C, Yki-Järvinen H.

J Clin Endocrinol Metab. 2015 Feb;100(2):607-16. doi: 10.1210/jc.2014-3050. Epub 2014 Nov 18.

PMID:
25405502
41.

Comparison of insulin glargine and liraglutide added to oral agents in patients with poorly controlled type 2 diabetes.

D'Alessio D, Häring HU, Charbonnel B, de Pablos-Velasco P, Candelas C, Dain MP, Vincent M, Pilorget V, Yki-Järvinen H; EAGLE Investigators.

Diabetes Obes Metab. 2015 Feb;17(2):170-8. doi: 10.1111/dom.12406. Epub 2014 Dec 7.

PMID:
25359159
42.

New insulin glargine 300 units/mL versus glargine 100 units/mL in people with type 2 diabetes using oral agents and basal insulin: glucose control and hypoglycemia in a 6-month randomized controlled trial (EDITION 2).

Yki-Järvinen H, Bergenstal R, Ziemen M, Wardecki M, Muehlen-Bartmer I, Boelle E, Riddle MC; EDITION 2 Study Investigators.

Diabetes Care. 2014 Dec;37(12):3235-43. doi: 10.2337/dc14-0990. Epub 2014 Sep 5.

PMID:
25193531
43.

Altered miRNA processing disrupts brown/white adipocyte determination and associates with lipodystrophy.

Mori MA, Thomou T, Boucher J, Lee KY, Lallukka S, Kim JK, Torriani M, Yki-Järvinen H, Grinspoon SK, Cypess AM, Kahn CR.

J Clin Invest. 2014 Aug;124(8):3339-51. doi: 10.1172/JCI73468. Epub 2014 Jul 1.

44.

Michaela Diamant, 11 April 1962-9 April 2014.

Heine RJ, Yki-Järvinen H, Kahn SE, van Raalte DH.

Diabetologia. 2014 Jul;57(7):1271-2. doi: 10.1007/s00125-014-3254-4. Epub 2014 May 6. No abstract available.

PMID:
24797287
45.

Non-alcoholic fatty liver disease as a cause and a consequence of metabolic syndrome.

Yki-Järvinen H.

Lancet Diabetes Endocrinol. 2014 Nov;2(11):901-10. doi: 10.1016/S2213-8587(14)70032-4. Epub 2014 Apr 7. Review.

PMID:
24731669
46.

Impact of non-alcoholic fatty liver disease on liver volume in humans.

Bian H, Hakkarainen A, Zhou Y, Lundbom N, Olkkonen VM, Yki-Järvinen H.

Hepatol Res. 2015 Jan;45(2):210-9. doi: 10.1111/hepr.12338. Epub 2014 Jul 18.

PMID:
24698021
47.

Gene polymorphisms of cellular senescence marker p21 and disease progression in non-alcohol-related fatty liver disease.

Aravinthan A, Mells G, Allison M, Leathart J, Kotronen A, Yki-Jarvinen H, Daly AK, Day CP, Anstee QM, Alexander G.

Cell Cycle. 2014;13(9):1489-94. doi: 10.4161/cc.28471. Epub 2014 Mar 11.

48.

PNPLA3 mediates hepatocyte triacylglycerol remodeling.

Ruhanen H, Perttilä J, Hölttä-Vuori M, Zhou Y, Yki-Järvinen H, Ikonen E, Käkelä R, Olkkonen VM.

J Lipid Res. 2014 Apr;55(4):739-46. doi: 10.1194/jlr.M046607. Epub 2014 Feb 7.

49.

A population-based study on the prevalence of NASH using scores validated against liver histology.

Hyysalo J, Männistö VT, Zhou Y, Arola J, Kärjä V, Leivonen M, Juuti A, Jaser N, Lallukka S, Käkelä P, Venesmaa S, Simonen M, Saltevo J, Moilanen L, Korpi-Hyövalti E, Keinänen-Kiukaanniemi S, Oksa H, Orho-Melander M, Valenti L, Fargion S, Pihlajamäki J, Peltonen M, Yki-Järvinen H.

J Hepatol. 2014 Apr;60(4):839-46. doi: 10.1016/j.jhep.2013.12.009. Epub 2013 Dec 12.

PMID:
24333862
50.

Effects of dietary interventions on liver volume in humans.

Bian H, Hakkarainen A, Lundbom N, Yki-Järvinen H.

Obesity (Silver Spring). 2014 Apr;22(4):989-95. doi: 10.1002/oby.20623. Epub 2013 Dec 4.

Supplemental Content

Loading ...
Support Center